Back

XtalPi signs Stanford drug discovery deal as shares rise 3.99%

Verifying
  • XtalPi subsidiary LCC Technologies signed a drug discovery agreement with Stanford University’s Board of Trustees.
  • 3.99% was XtalPi Holdings’ share-price increase, reaching HK$7.17 as of press time.
  • Stanford investigators may submit proposals for review by a joint steering committee.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.